Source brief: InfluenceAsia is linking to and indexing this publicly available Medical story for editorial review. The full article should be read at the original publisher.
Original source title
Roche KRAS drug succeeds in head-to-head lung cancer study
Source-provided summary
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
Read the original report
BioPharma Dive original article
Source and disclaimer
Source: This draft references publicly available reporting from BioPharma Dive. InfluenceAsia does not claim ownership of the original publisher's article text, images, reporting, trademarks or other protected material.
Legal disclaimer: This page is an editorial intake draft for review, attribution and linking. It is provided for general information only and should not be treated as financial, investment, legal, tax, medical or professional advice. Editors should verify rights, names, dates, figures, quotations, claims, image licenses and source context before publication. Do not publish full third-party article text unless InfluenceAsia has the necessary rights or permission.
